CDA | Evidence Driven
CDA | Evidence Driven

Kisqali for Metastatic Breast Cancer – Details

Details

Files
Generic Name:
Ribociclib
Project Status:
Complete
Therapeutic Area:
Advanced or Metastatic Breast Cancer
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Kisqali
Project Line:
Reimbursement Review
Project Number:
PC0112-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
200 mg
Tumour Type:
Breast
Indications:
Advanced or Metastatic Breast Cancer
Funding Request:
For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as an initial endocrine-based therapy
Pre Noc Submission:
Yes
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – pERC Final Recommendation Final Recommendation April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Final Clinical Guidance Report Guidance Reports April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Final Economic Guidance Report Guidance Reports April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – pERC Initial Recommendation Initial Recommendation March 29, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – PAG Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Manufacturer Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Patient Group Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Clinician Feedback on Initial Recommendation Feedback April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Patient Group COI Declarations COI Declarations April 18, 2018 View PDF
Ribociclib (Kisqali) Metastatic Breast Cancer – Clinician COI Declarations COI Declarations April 18, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : May 3, 2018